Incyte’s Q2 diversification gains are real, but Jakafi’s shadow still limits the rerating case

What happened

Incyte’s 2Q26 results deliver a modest but tangible validation of its diversification push, with 17% underlying net sales growth and broad-based portfolio expansion across dermatology, hematology, and oncology. Strong operating leverage is evident even after stripping out the one-time Opzelura CMS benefit, suggesting the underlying business is strengthening. Yet the hard reality remains: Jakafi still commands the lion’s share of revenue, and the 2028 exclusivity step-down remains a structural overhang that no single quarter can erase. The upcoming 2H26 clinical readouts—across atopic dermatitis label expansion, povorcitinib, and other pipeline assets—are now the pivotal catalysts for proving the multi-engine thesis is durable rather than a temporary narrative. Until those readouts confirm meaningful, sustained non-Jakafi scale, the market is likely to keep pricing the stock as a recovery story rather than a fully derisked growth franchise.

Implication

Investors should treat the 2Q26 beat as supportive but not conclusive, because the one-time CMS accrual reversal still flatters reported Opzelura economics and underlying prescription growth must be confirmed in Q3. The current valuation at ~$117 per share already prices in a successful EU launch and continued high double-digit growth from newer products, leaving little margin for error if any pipeline readout stumbles. A more attractive entry point remains near $105, while trimming above $130 still makes sense given the concentration risk and crowded bullish narrative. The next 6–12 months are a proof period: if Opzelura EU revenue scales rapidly and povorcitinib delivers clean data, the thesis shifts to full diversification and a higher base case becomes justified. Until then, the prudent course is to let the catalysts play out and buy on evidence, not on the article’s enthusiasm.

Thesis delta

The prior thesis emphasized waiting for proof that non-Jakafi products—led by Opzelura and the hematology/oncology portfolio—could narrow dependence on Jakafi before its 2028 LOE. The 2Q26 results provide early, albeit imperfect, evidence that diversification is progressing: underlying growth reached 17% and operating leverage improved, but the mix still relies heavily on Jakafi and the Opzelura benefit includes a one-time gross-to-net reversal that artificially boosts reported numbers. This updates the conviction slightly upward but does not alter the WAIT rating; we still need to see clean demand data and pipeline successes before treating the multi-engine story as de-risked.